
Mantle Cell Lymphoma
Latest News
Latest Videos

CME Content
More News

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.






















































